Lead Product(s): EYS606
Therapeutic Area: Ophthalmology
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 08, 2020
The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic non-infectious uveitis (NIU), including the launch of its Electro Study.